Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 27 | 2024 | 1223 | 6.430 |
Why?
|
Prostatic Neoplasms | 38 | 2024 | 11103 | 3.300 |
Why?
|
Hyaluronic Acid | 3 | 2024 | 484 | 1.580 |
Why?
|
Androgen Antagonists | 13 | 2024 | 1408 | 1.540 |
Why?
|
Prostate-Specific Antigen | 13 | 2024 | 2465 | 1.330 |
Why?
|
Prostatectomy | 10 | 2024 | 1825 | 1.140 |
Why?
|
Radiotherapy Dosage | 15 | 2024 | 2898 | 1.040 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2022 | 2020 | 0.830 |
Why?
|
Tumor Burden | 3 | 2024 | 1892 | 0.790 |
Why?
|
Endometrial Neoplasms | 5 | 2022 | 1365 | 0.770 |
Why?
|
Radiometry | 2 | 2024 | 812 | 0.720 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2023 | 801 | 0.720 |
Why?
|
Radiation Pneumonitis | 2 | 2018 | 102 | 0.680 |
Why?
|
Radiation Injuries | 3 | 2023 | 1191 | 0.650 |
Why?
|
Radiographic Image Enhancement | 2 | 2018 | 877 | 0.610 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2024 | 1655 | 0.580 |
Why?
|
Organs at Risk | 2 | 2016 | 359 | 0.530 |
Why?
|
Luminescence | 1 | 2016 | 108 | 0.530 |
Why?
|
Movement | 3 | 2007 | 1476 | 0.520 |
Why?
|
Ear Neoplasms | 1 | 2016 | 118 | 0.510 |
Why?
|
Calcinosis | 3 | 2010 | 1477 | 0.510 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2016 | 99 | 0.500 |
Why?
|
Ear Canal | 1 | 2016 | 148 | 0.500 |
Why?
|
Beta Particles | 1 | 2015 | 51 | 0.500 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2021 | 1520 | 0.500 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2017 | 140 | 0.480 |
Why?
|
Parotid Gland | 1 | 2015 | 176 | 0.460 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 505 | 0.450 |
Why?
|
Luminescent Measurements | 1 | 2015 | 340 | 0.440 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4908 | 0.430 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2577 | 0.420 |
Why?
|
Rectum | 3 | 2024 | 891 | 0.420 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 694 | 0.390 |
Why?
|
Prostate | 5 | 2024 | 1772 | 0.390 |
Why?
|
Radiotherapy | 2 | 2018 | 1498 | 0.390 |
Why?
|
Watchful Waiting | 5 | 2019 | 489 | 0.380 |
Why?
|
Tomography, X-Ray Computed | 6 | 2018 | 20600 | 0.380 |
Why?
|
Heart | 3 | 2010 | 4431 | 0.380 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 1989 | 0.370 |
Why?
|
Radiation Oncology | 3 | 2022 | 563 | 0.370 |
Why?
|
Retrospective Studies | 24 | 2024 | 80673 | 0.360 |
Why?
|
Radiosurgery | 4 | 2021 | 1339 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9278 | 0.350 |
Why?
|
Neoplasms, Experimental | 1 | 2015 | 1225 | 0.340 |
Why?
|
Aged | 32 | 2024 | 169266 | 0.320 |
Why?
|
Surgery, Computer-Assisted | 1 | 2016 | 1004 | 0.310 |
Why?
|
Respiration | 1 | 2015 | 1656 | 0.310 |
Why?
|
Salvage Therapy | 5 | 2023 | 1264 | 0.310 |
Why?
|
Male | 41 | 2024 | 360675 | 0.300 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3352 | 0.300 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2016 | 2025 | 0.290 |
Why?
|
Hodgkin Disease | 1 | 2015 | 1378 | 0.290 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2021 | 1784 | 0.280 |
Why?
|
Magnetic Resonance Imaging | 6 | 2023 | 36418 | 0.280 |
Why?
|
SEER Program | 4 | 2020 | 1450 | 0.270 |
Why?
|
Humans | 62 | 2024 | 761098 | 0.270 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3770 | 0.260 |
Why?
|
Artifacts | 4 | 2020 | 1913 | 0.250 |
Why?
|
Quality of Life | 2 | 2023 | 13362 | 0.240 |
Why?
|
Physical Phenomena | 1 | 2024 | 48 | 0.240 |
Why?
|
Combined Modality Therapy | 6 | 2020 | 8519 | 0.230 |
Why?
|
Survival Rate | 6 | 2020 | 12727 | 0.230 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13630 | 0.230 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13382 | 0.220 |
Why?
|
Middle Aged | 27 | 2024 | 220835 | 0.220 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 12467 | 0.220 |
Why?
|
Prognosis | 8 | 2024 | 29672 | 0.200 |
Why?
|
Databases, Factual | 7 | 2019 | 7969 | 0.200 |
Why?
|
Risk Assessment | 6 | 2023 | 24013 | 0.200 |
Why?
|
Atherosclerosis | 2 | 2007 | 3405 | 0.190 |
Why?
|
Belgium | 1 | 2021 | 118 | 0.190 |
Why?
|
Lung | 2 | 2017 | 9979 | 0.170 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 1223 | 0.160 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2018 | 9001 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11732 | 0.150 |
Why?
|
Urethra | 2 | 2021 | 405 | 0.150 |
Why?
|
Phantoms, Imaging | 4 | 2022 | 2515 | 0.150 |
Why?
|
ROC Curve | 1 | 2006 | 3582 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 696 | 0.150 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 532 | 0.140 |
Why?
|
Neoplasm Staging | 7 | 2021 | 11118 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2021 | 570 | 0.140 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6817 | 0.140 |
Why?
|
Acceleration | 2 | 2007 | 189 | 0.140 |
Why?
|
Propensity Score | 3 | 2021 | 1913 | 0.140 |
Why?
|
Carcinoma, Endometrioid | 1 | 2019 | 276 | 0.140 |
Why?
|
Algorithms | 4 | 2018 | 14023 | 0.140 |
Why?
|
Androgens | 1 | 2024 | 1283 | 0.130 |
Why?
|
Urethral Stricture | 1 | 2016 | 50 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2021 | 3512 | 0.130 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39121 | 0.130 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2138 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2023 | 5249 | 0.120 |
Why?
|
Vagina | 1 | 2020 | 841 | 0.120 |
Why?
|
Morbidity | 1 | 2019 | 1750 | 0.110 |
Why?
|
Cohort Studies | 7 | 2021 | 41486 | 0.110 |
Why?
|
Logistic Models | 5 | 2019 | 13254 | 0.110 |
Why?
|
Survival Analysis | 4 | 2019 | 10083 | 0.110 |
Why?
|
Regression Analysis | 2 | 2015 | 6343 | 0.110 |
Why?
|
Female | 18 | 2023 | 392458 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1051 | 0.110 |
Why?
|
Time Factors | 3 | 2021 | 39953 | 0.110 |
Why?
|
Radiotherapy, Conformal | 1 | 2016 | 548 | 0.110 |
Why?
|
Tidal Volume | 1 | 2015 | 488 | 0.100 |
Why?
|
Treatment Outcome | 6 | 2020 | 64670 | 0.100 |
Why?
|
Adult | 13 | 2023 | 221083 | 0.100 |
Why?
|
Travel | 1 | 2018 | 796 | 0.100 |
Why?
|
Kinetics | 2 | 2019 | 6312 | 0.100 |
Why?
|
Prospective Studies | 5 | 2023 | 54419 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 1116 | 0.100 |
Why?
|
Sample Size | 1 | 2015 | 841 | 0.100 |
Why?
|
Consensus | 1 | 2021 | 3133 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2018 | 20120 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1661 | 0.090 |
Why?
|
Disease Management | 2 | 2019 | 2508 | 0.090 |
Why?
|
Patient Compliance | 1 | 2020 | 2687 | 0.090 |
Why?
|
Cochlea | 1 | 2016 | 844 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2855 | 0.080 |
Why?
|
Catheters | 2 | 2023 | 426 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14676 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1615 | 0.080 |
Why?
|
Mice, Nude | 1 | 2015 | 3604 | 0.080 |
Why?
|
Aged, 80 and over | 9 | 2020 | 58946 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9324 | 0.080 |
Why?
|
United States | 7 | 2022 | 72337 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3196 | 0.070 |
Why?
|
Area Under Curve | 1 | 2010 | 1636 | 0.070 |
Why?
|
Filtration | 1 | 2006 | 228 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2820 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5427 | 0.060 |
Why?
|
Observer Variation | 1 | 2010 | 2611 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10213 | 0.060 |
Why?
|
User-Computer Interface | 1 | 2010 | 1395 | 0.060 |
Why?
|
Research Design | 1 | 2019 | 6178 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8000 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8236 | 0.050 |
Why?
|
Piroxicam | 1 | 2002 | 18 | 0.050 |
Why?
|
Odds Ratio | 3 | 2020 | 9648 | 0.050 |
Why?
|
Recurrence | 1 | 2015 | 8456 | 0.050 |
Why?
|
Child, Preschool | 2 | 2015 | 42217 | 0.050 |
Why?
|
Rhodamines | 1 | 2002 | 178 | 0.050 |
Why?
|
Risk Factors | 2 | 2019 | 74219 | 0.050 |
Why?
|
Polyglycolic Acid | 1 | 2002 | 406 | 0.050 |
Why?
|
Information Storage and Retrieval | 1 | 2006 | 818 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5879 | 0.040 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 3200 | 0.040 |
Why?
|
Colposcopy | 1 | 2021 | 149 | 0.040 |
Why?
|
Radioisotopes | 1 | 2021 | 501 | 0.040 |
Why?
|
Carcinosarcoma | 1 | 2020 | 106 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 849 | 0.040 |
Why?
|
Needles | 1 | 2022 | 451 | 0.040 |
Why?
|
Mice | 2 | 2016 | 81324 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2020 | 217 | 0.040 |
Why?
|
Selection Bias | 1 | 2020 | 359 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16947 | 0.040 |
Why?
|
Young Adult | 2 | 2015 | 59199 | 0.040 |
Why?
|
Linear Models | 1 | 2007 | 5869 | 0.040 |
Why?
|
Calcium | 1 | 2010 | 5720 | 0.040 |
Why?
|
Lactic Acid | 1 | 2002 | 1139 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6482 | 0.030 |
Why?
|
Child | 2 | 2015 | 80134 | 0.030 |
Why?
|
Adolescent | 2 | 2015 | 88271 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2019 | 590 | 0.030 |
Why?
|
Education | 1 | 2019 | 535 | 0.030 |
Why?
|
Software | 1 | 2010 | 4433 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 159 | 0.030 |
Why?
|
Heart Rate | 1 | 2007 | 4196 | 0.030 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2020 | 475 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 296 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 709 | 0.030 |
Why?
|
Polymers | 1 | 2002 | 1617 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2927 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3073 | 0.030 |
Why?
|
Myocardium | 1 | 2007 | 4746 | 0.030 |
Why?
|
Infant | 1 | 2016 | 36164 | 0.030 |
Why?
|
Biocompatible Materials | 1 | 2002 | 1684 | 0.030 |
Why?
|
Triage | 1 | 2021 | 984 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 422 | 0.030 |
Why?
|
Animals | 2 | 2016 | 168083 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 3803 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 460 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1966 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2006 | 4060 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 22125 | 0.030 |
Why?
|
Taxoids | 1 | 2015 | 668 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 1813 | 0.020 |
Why?
|
Markov Chains | 1 | 2015 | 965 | 0.020 |
Why?
|
Models, Economic | 1 | 2015 | 714 | 0.020 |
Why?
|
Patient Selection | 1 | 2022 | 4245 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1409 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3923 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2599 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20981 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3603 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3591 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8639 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6585 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2757 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2015 | 2000 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2019 | 3535 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2015 | 2553 | 0.020 |
Why?
|
Clinical Competence | 1 | 2020 | 4786 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9614 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12058 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5828 | 0.010 |
Why?
|
Chemistry, Physical | 1 | 2002 | 153 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5494 | 0.010 |
Why?
|
Chemical Phenomena | 1 | 2002 | 483 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18385 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2002 | 944 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13506 | 0.010 |
Why?
|
Microspheres | 1 | 2002 | 783 | 0.010 |
Why?
|
Particle Size | 1 | 2002 | 1649 | 0.010 |
Why?
|